| 摘要 |
This invention relates to anovel use of IL-1-ligand/IL-1 receptor disrupting compounds ( herein referred to as "IL-1beta Compounds"); such as small molecular compounds disrupting IL-1 ligand - IL-1 receptor interaction , IL-1 antibodies or IL-1 receptor antibodies, e.g. IL-1 binding molecules described herein, e.g. antibodies disclosed herein, e.g.IL-1 binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1 ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. jungenilerheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. |
